Radioimmunodetection of colorectal cancer

Kim, E. Edmund; DeLand, Frank H.; Casper, Scott E.; Corgan, Robert L.; Primus, F. James; Goldenberg, David M.

doi:10.1002/1097-0142(19800315)45:5+<1243::aid-cncr2820451334>3.0.co;2-1

Cited by 26 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use ofradioactive antibodies against certain tumor products for RaID has proved to be a new cancer detection modality (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). With affinity-purified antibodies to CEA, for example, RaID has been found to be a highly sensitive and specific method, even demonstrating tumor sites that were not revealed by more conventional techniques (3-5, 7).…”

Section: Discussionmentioning

confidence: 89%

“…Conversely, false-positivity and false-negativity were defined as positive or negative RaID results, respectively, in patients in whom either no tumor sites were known or found later or who did not have elevated serum hCG titers. It is known from other studies with CEA RaID, however, that CEA-positive tumors can be localized by RaID even ifthe plasma CEA titer is not elevated (3)(4)(5)7), so that the category offalse-positivity may need to be modified once tissue levels of the hCG target molecule are determined. Nevertheless, 10 out of 10 testicular cancer patients with proven tumor sites had positive RaID results, whereas three cases without known tumor were negative, thus yielding a sensitivity (truepositive rate) of 100% and a specificity (true-negative rate) of 100%.…”

Section: Resultsmentioning

confidence: 99%

“…However, aliver metastasis was missed by RaID in one ofthese lung cancer patients. Thus, of the total of 25 patients, 7 had normal hCG titers. All 18 with elevated hCG titers had evidence of tumor revealed by RaID, whereas two out ofseven cases were putatively false-positive and five out of seven were true-negative on the basis ofcirculating hCG titers (71% specificity).…”

Section: Resultsmentioning

confidence: 99%

“…In cancer, the use of antibodies directed against qualitatively distinct or quantitatively increased substances (tumor "markers") contained in neoplasms permits the visualization oftumor sites by this technology (1,2) and has been applied clinically to detect tumors bearing carcinoembryonic antigen (CEA), a-fetoprotein, and human chorionic gonadotropin (hCG) (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Goldenberg¹,

Kim²,

DeLand³

1981

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Radioimmunodetection (RaID) of tumors containing human chorionic gonadotropin (hCG; choriogonadotropin) was evaluated in 25 patients by injecting "3'I-labeled goat antibody IgG against hCG and performing total-body photoscans with a y scintillation camera 24 and 48 hr later. All 10 testicular cancer patients with proven tumor sites had positive RaID results, whereas three cases without known tumor were negative. Four patients with hydatidiform mole and one with degenerative products of conception showed positive RaID results consistent with elevated serum hCG titers. Two putatively false-positive results were obtained in patients with lung or ovarian cancer, whereas a false-negative metastasis to the liver ofa patient with lung cancer and an elevated serum hCG titer was observed. Of 14 tumor sites found by RaID in 10 testicular cancer patients, 4 were revealed by RaID prior to any other detection method used and provided a lead time to definitive diagnosis by other measures of a few days to >1 yr. Although arnumber ofpatients had high serum hCG levels, even exceeding 3 ,ug/ml, the xenogeneic antibody was capable oflocalizing in tumor. No adverse effects were noted in any of the patients studied. Thus, hCG RaID appears to be a safe and effective method of detecting and locating hCG-producing tumors and has been found to disclose occult testicular cancers.Radioimmunodetection (RaID) is the method by which antibodies are used to transport diagnostic amounts ofradioactivity to specific sites of the body for the external scintigraphic demonstration of abnormal sequestration of radioactivity in pathological tissues. In cancer, the use of antibodies directed against qualitatively distinct or quantitatively increased substances (tumor "markers") contained in neoplasms permits the visualization oftumor sites by this technology (1, 2) and has been applied clinically to detect tumors bearing carcinoembryonic antigen (CEA), a-fetoprotein, and human chorionic gonadotropin (hCG) (3-14).The application of RaID appears to be particularly indicated in patients in whom a tumor marker is shown to be increased in the blood, and where the sites of tumor or of marker production are suspected or unknown. We now communicate our experience with RaID using hCG antibodies, emphasizing the use of this approach to disclose occult metastases of testicular cancer.MATERIALS AND METHODS Subjects. RaID was applied to 25 consecutive patients with putative hCG-producing lesions. Thirteen had a history of histologically confirmed testicular cancer and were evaluated for the presence of primary, recurrent, or metastatic disease. In addition, five patients with hCG-secreting hydatidiform moles or uterine choriocarcinoma, patients with diverse ovarian and lung tumors, and a case with degenerative products of conception were included. Tumor sites were confirmed by surgery, biopsy, ultrasonography, radiological studies including computed tomography (CT), arteriography, venacavography, intravenous pyelography, and by other firm clinical evidence...

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Goldenberg¹,

Kim²,

DeLand³

1981

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…A more general detection of metastases is possible by injections of radiolabelled anti-CEA antibodies and study of the location of the antibody in the patient. In one series all of seven primary tumours were detected by scintillation scanning procedures and 20 of 25 metastatic sites (56). In one patient with a rapidly rising CEA level CAT and Tc scan together with ultrasound methods had failed to detect the tumour discovered by this radioimmunolocation (RIL) method.…”

Section: Localisation Of Metastasesmentioning

confidence: 99%

The detection and evaluation of human tumor metastases

Laurence

Neville

1983

Cancer Metast Rev

View full text Add to dashboard Cite

Many biochemical indices are purported to have clinical utility in the detection and management of neoplasia. Experience gained during the past decade tends to indicate their having a more important role in the detection and monitoring of metastases than of the primary lesion. From this present review of some of the commoner human tumours, it is concluded that such marker substances are important adjuncts in the management of germ cell and certain endocrine and endocrine-related tumours. The carcinoembryonic antigen (CEA) provides a marker for many gastrointestinal cancers, but there are no presently available substances with clinical usefulness for either breast or lung neoplasms. Alternative approaches to the detection of metastases are also presented. The particular use of antibody probes at an immunohistochemical level has been claimed to be able to detect micrometastastic disease in bone marrow or tumour-related monoclonal antibody probes may have application to other cancers in the future.

show abstract

Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein

Goldenberg¹,

Edmund²,

DeLand³

et al. 1980

Cancer

Self Cite

114

View full text Add to dashboard Cite

This study reports the use of radiolabeled antibodies to alpha-fetoprotein for the detection and localization of hepatocellular and germ cell carcinomas. Twelve patients with histories of histologically-confirmed neoplasia received a total dose between 1.0 and 4.4 mCi of 131I-labeled goat IgG prepared against human alpha-fetoprotein. Total-body photoscans were taken with a gamma scintillation camera at various intervals after injection of the radioactive antibody. Computer subtraction of radioactive technetium background images from the antibody 131I scans permitted the visualization of all tumor sites known to be present in 4 patients with either primary hepatocellular cancer or metastatic germ cell carcinoma of the testis. In contrast to the results with the specific antibody, radioactive normal goat IgG given to one of these patients with metastatic embryonal carcinoma of the testis failed to show equivalent localization. Among 8 patients with diverse neoplasms not believed to contain alpha-fetoprotein, 5 of 19 tumor sites showed radioactive antibody accretion, although significantly less than in the patients with liver or testicular cancer. Circulating antigen levels of up to 15,000 ng per milliliter did not prevent successful tumor imaging after intravenous injection of the radioantibody. This investigation indicates that alpha-fetoprotein-containing tumors can be detected and localized in vivo by the method of radioimmunodetection.

show abstract

Radioimmunodetection of colorectal cancer

Cited by 26 publications

References 7 publications

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

The detection and evaluation of human tumor metastases

Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein

Contact Info

Product

Resources

About